Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EORTC CLTF 2021 | Treatment of early-stage CTCL

Chalid Assaf • 14 Oct 2021
EORTC CLTF 2021
Cutaneous T-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Rare Diseases

Chalid Assaf, MD, PhD, Helios Klinikum Krefeld, Krefeld, Germany, gives an overview of the treatment of early-stage cutaneous T-cell lymphoma (CTCL), highlighting the use of locally-intensive therapies and commenting on the need to develop therapies which target symptoms. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.

More from Chalid Assaf

2:15
Updates on the brentuximab vedotin for CTCL
Chalid Assaf • 14 Oct 2021
3:21
Low-dose gemcitabine for advanced CTCL
Chalid Assaf • 14 Oct 2021
2:46
ALCANZA: brentuximab vedotin for CTCL
Chalid Assaf • 14 Oct 2021
1:26
Chlormethine gel for mycosis fungoides
Chalid Assaf • 14 Oct 2021

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals